CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Sufentanil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04959812
NCT04959812Phase 2Completed
CompareCT.gov

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

University of Texas Southwestern Medical Center·interventional·Posted Jul 13, 2021·Updated Jun 26, 2025

In Brief

A Phase 2 clinical trial evaluating Sufentanil and Placebo for Healthy. Completed, enrolled 46 participants across 2 sites.

Detailed Summary

This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 13, 2021
Enrollment StartMar 1, 2022
Primary CompletionSep 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.0 years ago

Interventions

Sufentanildrug

Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

Placeboother

Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.